Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Amortization of Deferred Charges (2022 - 2025)

Rani Therapeutics Holdings (RANI) has 4 years of Amortization of Deferred Charges data on record, last reported at $58000.0 in Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges changed 0.0% year-over-year to $58000.0; the TTM value through Sep 2025 reached $232000.0, changed 0.0%, while the annual FY2024 figure was $232000.0, 0.0% changed from the prior year.
  • Amortization of Deferred Charges reached $58000.0 in Q3 2025 per RANI's latest filing, roughly flat from $58000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $58000.0 in Q4 2022 and bottomed at $19000.0 in Q3 2022.
  • Average Amortization of Deferred Charges over 4 years is $55000.0, with a median of $58000.0 recorded in 2022.
  • The widest YoY moves for Amortization of Deferred Charges: up 205.26% in 2023, down 0.0% in 2023.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $58000.0 in 2022, then changed by 0.0% to $58000.0 in 2023, then changed by 0.0% to $58000.0 in 2024, then changed by 0.0% to $58000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $58000.0 in Q3 2025, $58000.0 in Q2 2025, and $58000.0 in Q1 2025.